Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New research shows no link between aromatase inhibitors and cardiovascular problems

17.04.2008
New evidence has emerged that, contrary to some current fears, aromatase inhibitors (AIs) are not associated with an increased risk of heart problems in women who take them to prevent their breast cancer recurring.

In a study presented today (Thursday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin, the researcher, Dr Alain Monnier, said that this was important and reassuring news for women.

AIs, such as letrozole, anastrozole and exemestane, work by causing severe oestrogen deprivation and, increasingly, they are being prescribed for women whose tumours are positive for the oestrogen receptor (ER+). Several trials have shown that AIs are more effective than tamoxifen – the gold standard for ER+ tumours; however, concerns have been raised about their effects on the cardiovascular system. In particular, the consequences of oestrogen deprivation can be atherosclerosis, high levels of lipids (fats) in the blood (hyperlipidaemia), high cholesterol levels (hypercholesterolaemia) and consequent heart problems.

Dr Monnier, a medical oncologist and head of the medical oncology department at the Centre Hospitalier de Belfort-Montbéliard (Belfort-Montbéliard, France), looked at the results from several trials of AIs in order to compare the effects of AIs versus tamoxifen and placebos on lipid levels and heart problems.

“One of the problems with obtaining clear evidence about the impact of AIs on cardiovascular health is that tamoxifen has cardioprotective effects,” explained Dr Monnier. “Tamoxifen is an anti-oestrogen with known lipid-lowering properties; it has been reported to reduce coronary plaques, C-reactive protein, and is associated with decreases in heart problems such as myocardial infarction. This makes comparisons between AIs and tamoxifen difficult to interpret, and so comparisons between AIs and placebos might indicate better the impact of AIs on cardiovascular health.”

After looking at results from several large trials, he found that in one trial (LEAP), which investigated the use of AIs in healthy postmenopausal women who had never had breast cancer, no significant differences were seen in total cholesterol levels between different AIs. In a second trial (MAP.1) letrozole was associated with a transient decrease in cholesterol levels.

In trials that compared AIs with tamoxifen, increases were seen in heart-related problems, but in another trial (MA17), which compared letrozole with placebo, there were no differences in hypercholesterolaemia or other cardiovascular problems.

“These results show that when compared with tamoxifen, adjuvant AI therapy has been associated with an increased incidence of hypercholesterolaemia, but this is probably due to the lipid-lowering effect of tamoxifen, and there is no significant increase in cardiovascular effects,” said Dr Monnier. “There seems to be little difference in cardiovascular profiles between individual AIs, and the relative increase in cardiovascular events in comparison to tamoxifen is not significant for letrozole, anastrozole or exemestane.

“Furthermore, the frequency of fatal heart attacks in the adjuvant AI trials is comparable with an age-matched population of postmenopausal women without breast cancer. This suggests that AIs do not increase the incidence of fatal cardiovascular complications, but lack the cardioprotective effects of tamoxifen.

“These findings are important and very reassuring about the safety of AIs. AIs are clearly superior to tamoxifen in terms of reducing the risk of breast cancer recurring. Also, we should not forget the life-threatening toxicities associated with tamoxifen therapy such as venous thromboembolism (VTE) and endometrial cancer, which do not appear to be a problem with AIs. While AIs have not demonstrated the lipid-lowering properties of tamoxifen, there is no evidence that a significant worsening of lipid levels occurs with their use.”

He concluded: “More postmenopausal women live free of their breast cancer recurring with AI therapy rather than with tamoxifen therapy. However, in this aging population, an increasing cardiovascular risk competes with cancer recurrence as a cause of mortality.”

Results from two AI trials (FACE and MA.27) are awaited and should provide more information on the impact of AIs on cardiovascular health.

Mary Rice | alfa
Further information:
http://www.ecco-org.eu

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>